Naoki Kurita, Hidekazu Nishikii, Yumiko Maruyama, Yasuhito Suehara, Keiichiro Hattori, Tatsuhiro Sakamoto, Takayasu Kato, Yasuhisa Yokoyama, Naoshi Obara, Kazushi Maruo, Tomohiro Ohigashi, Hitomi Yamaguchi, Toshiro Iwamoto, Hideto Minohara, Ryota Matsuoka, Koichi Hashimoto, Mamiko Sakata-Yanagimoto, Shigeru Chiba
Graft failure and delayed hematopoietic recovery are the major limitations of cord-blood transplantation (CBT). Romiplostim, a thrombopoietin-receptor agonist, promotes megakaryopoiesis and multilineage hematopoiesis in aplastic anemia. The decreased number of hematopoietic stem cells in the early phase after CBT and aplastic anemia share certain characteristics. Therefore, we hypothesized that romiplostim administration immediately after CBT may promote multilineage hematopoietic recovery. We investigated the safety and preliminary efficacy of administering romiplostim a day after CBT...
August 17, 2023: Annals of Hematology